Discover the symptoms, causes, types, diagnostics, and modern treatment methods for lymphoma. Check the prognosis and when to consult a specialist.
Table of Contents
- What is lymphoma? Definition and key information
- Types of lymphomas – classification and characteristics
- Causes of lymphoma development – risk factors
- Most common symptoms of lymphoma – how to recognize them?
- Lymphoma diagnostics – which tests to perform?
- Treatment and prognosis – modern lymphoma therapies
What is lymphoma? Definition and key information
Lymphoma is a general term for a group of cancers that originate from cells of the lymphatic system, specifically lymphocytes. The lymphatic system plays a crucial role in defending the body against infections and tumors, and its main components include lymph nodes, spleen, thymus, and bone marrow. Lymphomas develop when lymphocytes (most commonly type B or T) begin to divide uncontrollably, forming tumors within the lymphatic system, but they can also attack other organs such as the liver, lungs, or digestive tract. Unlike other blood-forming system cancers, such as leukemias, lymphomas typically manifest as enlarged lymph nodes, which may be palpable under the skin around the neck, armpits, or groin, or located deep in the abdominal cavity or chest. A characteristic feature of lymphomas is that they can affect people of all ages, though they are more common in adults and the elderly, with risk increasing with age.
There are two main types of lymphoma: Hodgkin lymphoma (formerly called malignant lymphoma) and non-Hodgkin lymphomas (NHL). Hodgkin lymphoma is characterized by the presence of specific Reed-Sternberg cells and generally has a better prognosis thanks to advanced modern treatment methods. Non-Hodgkin lymphomas are a more diverse group, comprising dozens of subtypes that may differ in growth rate, aggressiveness, and organ involvement. Lymphomas may develop slowly (indolent lymphomas), presenting symptoms for many years, or rapidly (aggressive lymphomas), requiring immediate medical intervention. Genetic factors, immune disturbances (e.g., due to AIDS or after organ transplantation), and certain viral infections, such as the Epstein-Barr virus or HTLV-I, may influence lymphoma development. The clinical picture of lymphoma is highly variable – from enlarged, painless lymph nodes to general symptoms such as fever, night sweats, weakness, or weight loss, as well as extranodal forms leading to significant dysfunction of affected organs. Due to the diversity of the disease course and malignancy levels, the diagnostics and treatment of lymphomas require an interdisciplinary approach involving hematologists, clinical oncologists, histopathologists, and other specialists. Early diagnosis and precise classification of lymphoma are crucial for selecting the appropriate treatment and achieving the best therapeutic outcomes.
Types of lymphomas – classification and characteristics
Lymphomas constitute an extremely diverse group of cancers of the lymphatic system and, depending on their nature, course, and prognosis, are divided into several categories. The most important division includes Hodgkin lymphoma (HL) and non-Hodgkin lymphomas (NHL), which differ in histopathological structure, population prevalence, and response to treatment. Hodgkin lymphoma, formerly known as malignant lymphoma, is distinguished by the presence of characteristic Reed-Sternberg cells under microscopic examination. This type most often affects young adults, and typical symptoms include enlarged lymph nodes, weight loss, fever, and night sweats. The disease usually develops slowly, and thanks to modern treatments, the prognosis for Hodgkin lymphoma is now very good. According to the World Health Organization (WHO) classification, there are several subtypes, including classical Hodgkin lymphoma (most commonly the mixed cellularity type) and lymphocyte-rich forms. In contrast, non-Hodgkin lymphomas comprise a diverse group of over 60 subtypes, most arising from B lymphocytes, less commonly from T lymphocytes or NK cells. Among non-Hodgkin lymphomas, there are aggressive, fast-growing forms and indolent lymphomas, developing more slowly, often over years without visible symptoms.
The most common non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL) – an aggressive, fast-occurring cancer that requires immediate treatment. It is characterized by considerable clinical and genetic heterogeneity, which is significant for prognosis and therapy selection. The second most common type is follicular lymphoma – a slow-growing form, often asymptomatic for a long time, though in some patients it may transform into a more aggressive disease. Other important types include mantle cell lymphoma, lymphoplasmacytic lymphoma, Burkitt lymphoma, and T-cell lymphomas, which are less common but often more challenging to treat. Of particular note is marginal zone lymphoma, which can develop in the spleen, lymph nodes, or other extranodal lymphatic tissues. Unique positions in the classification are primary central nervous system lymphomas and skin lymphomas, which require different therapeutic approaches. Each type of lymphoma possesses its own clinical picture, progression rate, and immunophenotypic features, which determine the diagnostic and treatment approach. Modern laboratory and molecular diagnostic methods, as well as advanced imaging, allow for increasingly precise differentiation of lymphoma subtypes, translating into more effective and personalized treatments. Understanding the complexities of lymphoma classification is key not just for physicians but also for patients, who can better comprehend their diagnosis, prognosis, and treatment options.
Causes of lymphoma development – risk factors
Lymphomas belong to cancers whose exact etiology remains the subject of ongoing research. However, it is known that a range of risk factors, environmental, immunological, and genetic, affect the development of this group of diseases. Foremost among them are disorders of the immune system, which increase susceptibility to abnormal lymphocyte division. People with primary immunodeficiencies, such as agammaglobulinemia or Wiskott-Aldrich syndrome, are statistically more likely to develop lymphomas. Secondary immunodeficiency – caused by long-term immunosuppressive treatment (e.g., after organ transplants), chronic steroid therapy, or HIV infection – also increases the risk. Additionally, certain chronic autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, or Sjögren’s syndrome, also raise the probability of developing lymphoma, likely due to ongoing lymphocyte activation and chronic inflammation. Viral and bacterial infections also play a role – it has been proven that infections with viruses like Epstein-Barr virus (EBV), HTLV-1, hepatitis C virus (HCV), and human herpesvirus 8 (HHV-8) significantly raise the risk of certain lymphoma subtypes, especially in individuals with weakened immunity. Chronic infection with Helicobacter pylori has been linked to the development of gastric MALT lymphoma. Environmental factors are significant as well – long-term exposure to some pesticides, organic solvents (e.g., benzene, toluene), or herbicides can increase the risk, particularly in people working in agriculture and the chemical industry.
Genetic and familial predispositions are important as well. Individuals with a family history (especially parents or siblings) of lymphoma or other blood cancers are at somewhat greater risk, though not as strongly as for breast or colorectal cancers. Mutations in genes responsible for regulating lymphocyte growth and differentiation, such as changes in the BCL2, TP53, or MYC genes, can promote uncontrolled growth of cancerous cells. The risk of lymphoma also rises with age – it is most common in people over 60, although certain types (e.g., Hodgkin lymphoma) can affect younger adults more often. Men are generally slightly more likely to develop lymphoma than women, although this difference is small and depends on the lymphoma type. Other potential risk factors include exposure to ionizing radiation (e.g., due to radiotherapy or occupational exposure), chronic inflammation, and certain hematological conditions such as Sjögren’s syndrome or chronic lymphocytic leukemia. It should be emphasized that the presence of one or even several risk factors does not mean an individual will necessarily develop lymphoma, and for many patients a specific cause cannot be identified. However, awareness of predisposing factors can lead to earlier detection and initiation of appropriate diagnostics, especially in high-risk groups.
Most common symptoms of lymphoma – how to recognize them?
Lymphomas are among the cancers that may develop insidiously for a long time, without provoking clear symptoms. Nonetheless, there are characteristic symptoms to watch for, especially if they persist or occur without obvious cause. The most typical and often the first signal of lymphoma is painless enlargement of lymph nodes, particularly in the neck, armpits, or groin. Unlike lymph node enlargement due to infection, lymph nodes in lymphoma are usually firm, painless, may merge into larger masses, and do not diminish in size after antibiotics. Over time, other general symptoms, known in medical terminology as B symptoms, may appear. These include night sweats – often profuse, leading to changing bed linens or pajamas, unintended weight loss greater than 10% of body weight over six months, and unexplained fever or low-grade fever. Some patients also suffer from severe itching, which can be very persistent and does not respond to standard dermatological treatments. These symptoms can easily be mistaken for those of other chronic or infectious diseases, often resulting in delayed diagnosis.
As the disease progresses, symptoms arising from infiltration of various organs and tissues may develop. If the cancer is located in the chest, it can cause pressure on the bronchi and lungs, manifesting with cough, shortness of breath, chest pain, or even difficulty swallowing. Abdominal lymphomas cause an increase in abdominal circumference, fullness, abdominal pain, and indigestion; in some cases, they may lead to intestinal obstruction or ascites. Patients may also experience general weakness, chronic fatigue, and lack of energy, which result from anemia due to bone marrow involvement or the chronic disease process. There may also be lowered immunity, as evidenced by recurrent infections, slow-healing wounds, or herpes outbreaks. More rarely, lymphoma can cause bone pain, limb swelling – especially if the cancer blocks lymphatic drainage – or bleeding if blood clotting is impaired. All these symptoms can appear alone or in various combinations depending on the location, type, and advancement of the lymphoma. Remember that not every lymph node enlargement or fatigue equals cancer, but persistent, unusual symptoms should always prompt a medical consultation and detailed diagnostics, especially in high-risk individuals or those with a family cancer history. Early detection of lymphoma gives a chance for effective treatment and the avoidance of serious complications.
Lymphoma diagnostics – which tests to perform?
The diagnostic process for lymphoma is complex and multi-stage, due to the variety of these cancers and the necessity to precisely determine the type to plan effective treatment. The first step is usually a thorough medical interview and physical examination, focusing on enlarged lymph nodes, spleen, or other lymphatic organs, as well as general symptoms (including fever, night sweats, weight loss). The key diagnostic test is a biopsy of the affected lymph node or suspect tissue. Removal of the entire lymph node (excisional biopsy) provides the most reliable results – the obtained material is then examined under a microscope by a pathologist, who assesses tissue architecture and identifies cancer cells’ features. Immunohistochemical studies are also essential as they allow precise differentiation between Hodgkin and non-Hodgkin lymphomas and determine the cancer subtype. Additional cytogenetic and molecular tests such as FISH (fluorescence in situ hybridization) or PCR detect genetic changes characteristic for certain types, which is especially important for targeted therapies.
Besides histopathological exams, extensive imaging diagnostics is required to assess the disease’s advancement and identify abnormalities throughout the body. The most commonly used imaging methods are CT (computed tomography) of the chest, abdomen, and pelvis, as well as MRI (magnetic resonance imaging) and PET-CT (positron emission tomography-computed tomography), which detects even small cancerous foci and assesses metabolic activity of lesions. Ultrasound (USG) is also used, particularly to assess superficial or abdominal lymph nodes. Basic blood tests include complete blood count with differential and LDH (lactate dehydrogenase), whose elevated levels may indicate high tumor activity. Liver and kidney functions are also checked, and serological tests for viruses linked to lymphoma (e.g., HIV, Epstein-Barr virus, hepatitis B and C) are performed. In some cases, bone marrow sampling (aspiration and trephine biopsy) is necessary, especially to evaluate blood-producing system involvement. The complex diagnostic process enables not only confirmation and subtyping of lymphoma, but also a precise assessment of the disease stage according to international classifications, which has a direct impact on treatment strategy and patient prognosis.
Treatment and prognosis – modern lymphoma therapies
Lymphoma treatment is highly individualized and depends on the type, stage, and the patient’s general condition. Modern oncohematology offers a wide array of therapeutic methods. The treatment strategy is determined by a multidisciplinary team based on precise diagnostics. One of the basic methods remains chemotherapy, often combined with immunotherapy or radiotherapy. Chemotherapy protocols such as ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for Hodgkin lymphoma and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for non-Hodgkin lymphomas are the gold standard for many lymphoma types. A significant advancement has been the use of monoclonal antibodies targeting specific antigens on tumor cells. Rituximab, along with newer drugs such as obinutuzumab or polatuzumab vedotin, has markedly improved the prognosis for B-cell lymphoma patients. Immunotherapies, including immune checkpoint inhibitors and bispecific antibodies, enable effective treatment even in cases resistant to previous therapies. Targeted molecular therapies and other targeted approaches, including tyrosine kinase inhibitors (ibrutinib, acalabrutinib in mantle cell and lymphoplasmacytic lymphoma), block specific signaling pathways necessary for cancer cell growth.
A groundbreaking development for resistant or relapsed lymphomas is CAR-T cell therapy, which involves modifying the patient’s own T lymphocytes to recognize and destroy cancer cells. CAR-T therapy can bring long-term remissions even in patients for whom standard treatments have failed. In selected cases, especially in younger patients or those with relapsed, aggressive disease, hematopoietic stem cell transplantation (autologous or allogeneic) may be considered. Radiotherapy remains essential for Hodgkin lymphoma and localized forms, whereas in advanced, aggressive lymphomas it is mainly used in combination with other methods. The effectiveness and prognosis of treatment depend not only on lymphoma type, but also on stage, patient age and condition, and response to therapy. Contemporary treatments allow for complete cure in up to 80% of Hodgkin lymphoma cases, as well as many years of survival for some indolent non-Hodgkin lymphomas. However, in more aggressive forms such as DLBCL or mantle cell lymphoma, prognosis varies and depends on prompt initiation of appropriate therapy. Ongoing clinical studies aim to find new methods and drug combinations to improve efficacy, minimize side effects, and enhance patient quality of life. Regular assessment of treatment response – with PET/CT imaging and molecular markers – allows for individually tailored strategies and increases the chance of achieving long-term remission or cure.
Summary
Lymphoma is a group of lymphatic system cancers whose effective treatment depends on rapid diagnosis and proper therapy. Early symptoms such as painless lymph node enlargement, chronic fatigue, or night sweats should be alarming and prompt detailed diagnostics. The diversity of lymphoma types and the impact of environmental and genetic risk factors highlight the importance of prevention and disease awareness. Modern treatment methods, including chemotherapy and radiotherapy, significantly improve prognosis. Remember – a quick visit to a specialist and starting therapy offer the best chance for recovery.
